Comparative Pharmacology
Head-to-head clinical analysis: CARDIOQUIN versus QUINORA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOQUIN versus QUINORA.
CARDIOQUIN vs QUINORA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class IA antiarrhythmic agent; blocks sodium channels, slows phase 0 depolarization, prolongs action potential duration, and increases effective refractory period. Also exhibits anticholinergic and negative inotropic effects.
Quinora (quinidine) is a Class Ia antiarrhythmic agent that blocks sodium channels, prolonging the action potential duration and effective refractory period. It also exhibits anticholinergic and negative inotropic effects.
Quinidine gluconate extended-release: 324-648 mg orally every 8-12 hours. Quinidine sulfate immediate-release: 200-400 mg orally every 6 hours. Quinidine sulfate extended-release: 300-600 mg orally every 8-12 hours. Maximum dose: 3-4 g/day.
325 mg orally every 4 to 6 hours as needed, not to exceed 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in patients with normal renal function. Prolonged in renal impairment (up to 16-40 hours) and heart failure, requiring dose adjustment.
5-7 hours; prolonged in hepatic impairment (up to 12-15 hours) and in elderly patients.
Renal: 60-80% as unchanged drug and metabolites (primarily hydroxylated metabolites). Biliary/fecal: 20-40%.
Primarily hepatic (biliary) excretion into feces (~80-90%); renal excretion of unchanged drug accounts for ~10-20%.
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent